Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 719 | 719 | 719 |
Full Text Views | 11 | 11 | 11 |
PDF Downloads | 13 | 13 | 13 |
In July 2022, mpox was declared an international public health emergency because of a surge in cases across Europe and America. This study assessed transmission dynamics and factors associated with hospitalization during the 2022 mpox outbreak in Peru. We performed a cross-sectional study using the Surveillance System of the National Center of Epidemiology, Prevention, and Disease Control (CDC-Peru) data. We estimated the basic reproduction number (R0), effective reproduction number (Rt), and the duration of the outbreak phases. We conducted mathematical modeling of the outbreak and estimated the serial interval. Additionally, we used Poisson regression with robust variance to identify hospitalization factors, using prevalence ratio. Between July and December 2022, 3,677 confirmed cases (96.3% male, mean age 32.6 years) were reported to the CDC-Peru. Of these, 75.0% were men who have sex with men (MSM), 55.6% had HIV infection, and 5.2% were hospitalized. The R0 was 2.37, with an exponential growth phase lasting 7 weeks, and Rt dropped to non-epidemic levels after 14 weeks. The incubation period and recovery period were estimated to be 6 days and 22 days, respectively. The serial interval was 9.3 days. HIV infection increased hospitalization risk. The 2022 mpox outbreak in Peru was characterized by primarily affecting a young MSM population, with a significant proportion being people living with HIV. Hospitalization was associated with HIV coinfection. This outbreak showed exponential growth during the first 7 weeks, followed by a marked deceleration of transmission.
Financial support: This project received funding from the National Center of Epidemiology, Prevention, and Disease Control (CDC-Peru). Reyes-Vega y Soriano-Moreno are supported by the Emerge: Emerging Diseases Epidemiology Research Training Grant from the Fogarty International Center of the
Disclosures: This work was supported by the National Center of Epidemiology, Prevention, and Disease Control (CDC-Peru). The funder had no role in the conceptualization of the paper or in the material presented. Most authors work at CDC-Peru. However, the opinions expressed in this article are those of the authors and do not necessarily reflect the policy or official position of the institutions where the authors work. The study was approved by the ethics committee on research at the National Institute of Health of Peru (INS) (#OE-042-22–Letter No. 2442-2022-OGITT/INS) and has approval from CDC-Peru (file No. 20230000535).
Current contact information: M. Gabriela Soto-Cabezas, Adrián Vásquez-Mejía, Martha Calderón, Mary Reyes-Vega, Yrene I. Blancas-Blas, Anderson N. Soriano-Moreno, María A. Vargas Huapaya, Kely R. Meza, Jorge R. Uchuya, Diego Castro-Garro, Sergio Luque-Mamani, Oswaldo G. E. Espinoza-Hurtado, and Cesar V. Munayco, Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, Lima, Perú, E-mails: msoto@minsa.gob.pe, apvasquez.md@gmail.com, mcalderon@dge.gob.pe, mreyes@dge.gob.pe, yblancas@dge.gob.pe, anderson.soriano@upch.pe, mvargas@dge.gob.pe, kelymeza@gmail.com, juchuya@dge.gob.pe, castrogda@gmail.com, serluquem@gmail.com, ozzespinoza27@gmail.com, and cmunayco@minsa.gob.pe.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 719 | 719 | 719 |
Full Text Views | 11 | 11 | 11 |
PDF Downloads | 13 | 13 | 13 |